Production of cheaper alternatives to name brand obesity drugs will stop on Wednesday

By Sydney Lupkin

Published March 18, 2025 at 5:29 PM EDT

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

Stories From This Author

5 takeaways from the confirmation hearing for Trump's FDA nominee

Sydney Lupkin

Dr. Marty Makary, President Trump's pick to run the Food and Drug Administration, faced questions from the Senate HELP Committee on the abortion pill, vaccines, FDA firings and chemicals in food.
Consumers can buy Zepbound and Wegovy direct from drugmakers if they pay cash

Sydney Lupkin

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount 鈥� but only if they skip their insurance. Novo Nordisk is now discounting Wegovy for cash customers too.
Ethics letters for Trump's picks to lead Medicare and NIH show they'll divest stock

Sydney Lupkin

Dr. Mehmet Oz, nominated to run the Centers for Medicare & Medicaid Services, will sell shares in Eli Lilly and UnitedHealth. Dr. Jay Bhattacharya, NIH nominee, will shed stock in Walmart and Nvidia.

瓜神app